A recent article, (Song et al. 2023) studied the effects of altering specific regions of a type 1 diabetes (T1D) autoantigen, the X-idiotype a 16 residues long peptide that is known to activate CD4+ T cells more effectively than insulin, could aid in designing a vaccine to treat this disease. Here, INS is linked to type 1 diabetes mellitus.